SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

ACCG-2671

GPCR·Structure Therapeutics Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1/2a
Time to market
Given that ACCG-2671 is still in Phase 1/2a, potential approval is likely many years away (probably 2029-2031 at the earliest), assuming successful clinical development.
Why 4/10
The next hard, dated catalyst is the multiple-ascending-dose (MAD) data from the Phase 1/2a trial, expected in the first half of 2027 (1H 2027), which is more than 6 months away. ACCG-2671 is an early-stage asset at a company whose lead program is aleniglipron (Phase 3), so this drug is not the primary value driver.
Actionable Insight NEUTRAL

ACCG-2671 is a very early-stage (Phase 1/2a) oral amylin receptor agonist for obesity. The single-dose data from September 2026 showed a ~6-day half-life, up to 3.3% body weight loss, and no serious adverse events in 31 healthy adults. The next catalyst is the MAD (multiple ascending dose) data expected in 1H 2027, which will show whether the weight-loss signal persists with repeat dosing. Investors should watch for whether the MAD data confirms a competitive profile versus other oral amylin agonists in development at Novo Nordisk and others.

Price Chart

Loading chart...

Executive Summary

ACCG-2671 is an early-stage, oral small-molecule dual amylin and calcitonin receptor agonist (DACRA) being developed by Structure Therapeutics (GPCR) for obesity and metabolic conditions. In September 2026, the company reported positive Phase 1/2a single-dose data showing a ~6-day half-life, up to 3.3% body weight loss, and no serious adverse events in 31 healthy adults. The next catalyst is multiple-ascending-dose data expected in the first half of 2027. ACCG-2671 is a secondary pipeline asset behind Structure's lead program, aleniglipron (an oral GLP-1 receptor agonist now in Phase 3). The stock trades near $21, down sharply from its 52-week high of $95, with a strong-buy analyst consensus and a mean price target of ~$104 implying ~380% upside, though this reflects the broader pipeline rather than ACCG-2671 alone.

How It Works

ACCG-2671 is an oral (pill) small molecule that activates the amylin and calcitonin receptors. Amylin is a hormone that works alongside GLP-1 to signal fullness and reduce food intake. Unlike injectable weight-loss drugs, this one is taken by mouth. It is a dual amylin and calcitonin receptor agonist (DACRA).

Trial Status

A Phase 1/2a single ascending dose (SAD) study in 31 healthy adults without obesity completed and reported positive topline data on September 8, 2026. A multiple ascending dose (MAD) portion is ongoing, with data expected in the first half of 2027.

The Two-Sided Case

▲ Bull Case5
Oral formulation could be a major advantage over injectable obesity drugs if efficacy is confirmed in later trials.
The ~6-day half-life suggests potential for weekly or less-frequent oral dosing, which would be differentiated.
Up to 3.3% weight loss in a single-dose study in healthy non-obese adults is an encouraging early signal, especially with no serious adverse events.
Structure Therapeutics has $1.24 billion in cash (as of Q3 2026), funding operations through 2028, so ACCG-2671 development is well-capitalized.
The broader analyst consensus is strong buy (21 buy/strong-buy vs 2 hold, 0 sell), and the mean price target of ~$104 implies significant upside for the stock.
▼ Bear Case5
ACCG-2671 is very early stage (Phase 1/2a SAD only); the 3.3% weight loss came from a single dose in only 31 healthy non-obese adults, not a repeat-dose obesity study.
The MAD data (1H 2027) is the real test; single-dose weight loss often does not translate to sustained, clinically meaningful weight reduction.
The obesity market is intensely competitive with Novo Nordisk (Wegovy, oral amycretin), Eli Lilly (Zepbound, orforglipron), and others far ahead in development.
Structure's stock has fallen from a 52-week high of ~$95 to ~$21, reflecting market skepticism about the broader pipeline, including the lead program aleniglipron.
Several tracked institutional investors exited or trimmed GPCR positions in Q2 2026, including Balyasny (exit), Pentwater (exit), and T. Rowe Price (trimmed 57.7%).

Upcoming Catalysts

  • MAD (multiple ascending dose) data from the Phase 1/2a trial expected in 1H 2027.
  • Aleniglipron (lead program) Phase 3 ACCOMPLISH program data readouts, which could indirectly affect sentiment for ACCG-2671 as part of the same pipeline.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Structure Therapeutics Inc. PRESS-RELEASE GPCR ·Originating report

Sources · 6

Hover a chip for the title
1 rttnews.com2 msn.com3 theglobeandmail.com4 wboc.com5 insidermonkey.com6 sec.gov